JW Lifescience Corporation (KRX:234080)

Market Cap	226.54B
Revenue (ttm)	248.30B
Net Income (ttm)	47.59B
Shares Out	15.48M
EPS (ttm)	3,073.31
PE Ratio	4.76
Forward PE	n/a
Dividend	500.00 (3.49%)
Ex-Dividend Date	Dec 27, 2024

Volume	48,646
Average Volume	121,635
Open	14,410
Previous Close	14,630
Day's Range	14,300 - 14,890
52-Week Range	10,000 - 15,580
Beta	0.42
RSI	55.87
Earnings Date	Feb 5, 2026

About JW Lifescience

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 297
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 234080

Financial Performance

In 2024, JW Lifescience's revenue was 222.48 billion, an increase of 7.55% compared to the previous year's 206.86 billion. Earnings were 43.99 billion, an increase of 56.29%.